US regenerative medicine firm Forever Labs has formally spun out SuperShot as a standalone business, a move the company says will allow both entities to sharpen their focus on growth and innovation.
Kevin Virgil has been appointed as the new chief executive of Forever Labs, replacing company co-founder Steven Clausnitzer, who will now lead SuperShot alongside co-founder Mark Katakowski. Both businesses will remain closely aligned, according to the announcement.
Mr Clausnitzer described the transition as “a natural evolution” and said SuperShot had matured to the point that “it deserves dedicated leadership and resources.” The move, he added, “sets the stage” for both companies to thrive independently while maintaining ties.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze